Investment Analysts’ Recent Ratings Updates for Taysha Gene Therapies (TSHA)

Taysha Gene Therapies (NASDAQ: TSHA) has recently received a number of price target changes and ratings updates:

• 12/4/2025 – Taysha Gene Therapies was given a new $11.00 price target on by analysts at The Goldman Sachs Group, Inc..
• 12/4/2025 – Taysha Gene Therapies was given a new $11.00 price target on by analysts at UBS Group AG.
• 12/4/2025 – Taysha Gene Therapies was upgraded by analysts at The Goldman Sachs Group, Inc. to a “buy” rating.
• 12/1/2025 – Taysha Gene Therapies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Taysha Gene Therapies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Taysha Gene Therapies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/14/2025 – Taysha Gene Therapies had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $13.00 price target on the stock.
• 11/8/2025 – Taysha Gene Therapies was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/5/2025 – Taysha Gene Therapies was given a new $8.00 price target on by analysts at JMP Securities.
• 11/5/2025 – Taysha Gene Therapies had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 11/5/2025 – Taysha Gene Therapies had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
• 11/5/2025 – Taysha Gene Therapies had its price target raised by analysts at Citizens Jmp from $6.00 to $8.00. They now have a “market outperform” rating on the stock.
• 10/30/2025 – Taysha Gene Therapies had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/21/2025 – Taysha Gene Therapies is now covered by analysts at Raymond James Financial, Inc.. They set a “strong-buy” rating and a $13.00 price target on the stock.
• 10/17/2025 – Taysha Gene Therapies had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
• 10/17/2025 – Taysha Gene Therapies had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.

Insider Activity

In related news, insider Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the sale, the insider owned 1,006,439 shares of the company’s stock, valued at approximately $4,539,039.89. This trade represents a 20.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 570,172 shares of company stock worth $2,341,906 in the last three months. Company insiders own 3.78% of the company’s stock.

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.